JP2017533248A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533248A5
JP2017533248A5 JP2017525075A JP2017525075A JP2017533248A5 JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5 JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridin
oxo
enyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533248A (ja
JP6669744B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060003 external-priority patent/WO2016077378A1/en
Publication of JP2017533248A publication Critical patent/JP2017533248A/ja
Publication of JP2017533248A5 publication Critical patent/JP2017533248A5/ja
Application granted granted Critical
Publication of JP6669744B2 publication Critical patent/JP6669744B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525075A 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン Expired - Fee Related JP6669744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077703P 2014-11-10 2014-11-10
US62/077,703 2014-11-10
PCT/US2015/060003 WO2016077378A1 (en) 2014-11-10 2015-11-10 Substituted pyrrolopyrdines as inhibitors of bromodomain

Publications (3)

Publication Number Publication Date
JP2017533248A JP2017533248A (ja) 2017-11-09
JP2017533248A5 true JP2017533248A5 (cg-RX-API-DMAC7.html) 2018-12-20
JP6669744B2 JP6669744B2 (ja) 2020-03-18

Family

ID=54608969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525075A Expired - Fee Related JP6669744B2 (ja) 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン

Country Status (6)

Country Link
US (1) US10183009B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6669744B2 (cg-RX-API-DMAC7.html)
CN (3) CN116003409A (cg-RX-API-DMAC7.html)
MA (1) MA40943A (cg-RX-API-DMAC7.html)
WO (1) WO2016077378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
MX2015014701A (es) 2013-04-24 2016-08-08 Salk Inst For Biological Studi Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica.
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY207899A (en) 2014-04-23 2025-03-27 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック, インコーポレイテッド ブロモドメインインヒビターおよびその使用
CN107531692B (zh) 2015-01-29 2020-12-25 基因泰克公司 治疗化合物及其用途
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
DK3472157T3 (da) * 2016-06-20 2023-05-01 Incyte Corp Krystallinske faste former af en bet-inhibitor
TW201825490A (zh) * 2017-01-11 2018-07-16 大陸商江蘇豪森藥業集團有限公司 吡咯並[2,3-c]吡啶類衍生物、其製備方法及其在醫藥上的應用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110198941B (zh) * 2017-01-25 2021-09-28 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
WO2018188047A1 (en) * 2017-04-14 2018-10-18 Abbvie Inc. Bromodomain inhibitors
WO2019023149A1 (en) * 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
MX2020006612A (es) 2017-12-20 2020-11-09 Betta Pharmaceuticals Co Ltd Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
CN109970733B (zh) * 2017-12-28 2020-05-08 新发药业有限公司 一种维罗非尼及其类似物的简便制备方法
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
CN110577526B (zh) * 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
WO2020007322A1 (zh) * 2018-07-04 2020-01-09 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN110776508B (zh) 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN110818609A (zh) * 2018-08-11 2020-02-21 中国药科大学 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途
WO2020132004A1 (en) * 2018-12-20 2020-06-25 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
EP3917526A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN115052594B (zh) 2020-01-29 2024-07-16 福宏治疗公司 化合物和其用途
EP4114392A4 (en) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
CN115667254A (zh) * 2020-05-21 2023-01-31 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2023536139A (ja) * 2020-07-29 2023-08-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4540226A1 (en) 2022-06-16 2025-04-23 Amphista Therapeutics Ltd Bifunctional molecules for targeted protein degradation
WO2024057021A1 (en) 2022-09-13 2024-03-21 Amphista Therapeutics Limited Compounds for targeted protein degradation
WO2024193527A1 (zh) * 2023-03-20 2024-09-26 山东新时代药业有限公司 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物
WO2025117674A1 (en) * 2023-11-28 2025-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
GB202319256D0 (en) 2023-12-15 2024-01-31 Amphista Therapeutics Ltd Novel compounds for targeted protein degradation
WO2025191109A1 (en) 2024-03-13 2025-09-18 Amphista Therapeutics Limited Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE69507956T2 (de) 1994-07-21 1999-09-09 Akzo Nobel N.V. Zyklische keton peroxyde zubereitungen
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag, Basel Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE213730T1 (de) 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT980244E (pt) 1997-05-06 2003-10-31 Wyeth Corp Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
AU763626B2 (en) 1998-11-19 2003-07-31 Warner-Lambert Company N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl)-acrylamide, an irreversible inhibitor of tyrosine kinases
JP2007291059A (ja) * 2005-11-21 2007-11-08 Japan Tobacco Inc ヘテロ環化合物およびその医薬用途
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20140094456A1 (en) * 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
WO2014164780A1 (en) 2013-03-11 2014-10-09 Abbvie Inc. Fused tetracyclic bromodomain inhibitors
CA2903910C (en) * 2013-03-12 2023-08-15 Steven D. FIDANZE Triazadibenzo[cd,f]azulene derivatives and pharmaceutical compositions thereof useful as bromodomain inhibitors
CN104211639A (zh) 2013-06-05 2014-12-17 中国科学院上海药物研究所 一类炔基杂环类化合物及其应用
CA2915054A1 (en) 2013-06-12 2014-12-18 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
RU2016102647A (ru) 2013-06-28 2017-08-01 Эббви Инк. Ингибиторы бромодомена
US9399640B2 (en) * 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN110452216B (zh) * 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
MY207899A (en) * 2014-04-23 2025-03-27 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック, インコーポレイテッド ブロモドメインインヒビターおよびその使用
JP6771464B2 (ja) 2014-11-27 2020-10-21 ジェネンテック, インコーポレイテッド Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
EP3247353A4 (en) * 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN107531692B (zh) 2015-01-29 2020-12-25 基因泰克公司 治疗化合物及其用途
JP6512051B2 (ja) * 2015-09-28 2019-05-15 株式会社Jvcケンウッド 端末装置、通信システム、通信方法、プログラム

Similar Documents

Publication Publication Date Title
JP2017533248A5 (cg-RX-API-DMAC7.html)
JP2017533249A5 (cg-RX-API-DMAC7.html)
JP2017533250A5 (cg-RX-API-DMAC7.html)
JP2019516757A5 (cg-RX-API-DMAC7.html)
JP2017530176A5 (cg-RX-API-DMAC7.html)
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
CN101039673B (zh) 用于治疗涉及细胞增殖的疾病的组合
TWI699355B (zh) 喹唑啉化合物
Roth et al. Nintedanib: from discovery to the clinic
TWI556820B (zh) Hsp90抑制劑之組合
JP6669745B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
TWI324159B (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
JP2017537100A5 (cg-RX-API-DMAC7.html)
BRPI0813999A2 (pt) ciclopentanos de pirimidil como inibidores de akt proteína cinase
JP2017526696A5 (cg-RX-API-DMAC7.html)
JP2018510851A5 (cg-RX-API-DMAC7.html)
EP4225383A1 (en) Modulators of cell proliferation and uses thereof
JP2018501287A5 (cg-RX-API-DMAC7.html)
JP2012515737A (ja) メトトレキサートおよびdhodh阻害剤を含む組合せ剤
JP2019512535A5 (cg-RX-API-DMAC7.html)
JP2017525740A5 (cg-RX-API-DMAC7.html)
JP2010523677A (ja) 癌の治療のためのPI3Kα阻害剤としてのピリド[2,3−D]ピリミジン−7−オン
JP2017501983A5 (cg-RX-API-DMAC7.html)
JP2015514796A5 (cg-RX-API-DMAC7.html)
AU2013254468A1 (en) Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg